A recent study compared two dosages of ifinatamab deruxtecan among patients with extensive-stage small cell lung cancer.

NSCLC, adding nivolumab to tivozanib in metastatic RCC underwhelms, and T-DXd shows improvement in HER2+ breast cancer with brain metastases.

The European Society for Medical Oncology’s annual meeting this week featured the hottest emergent areas of cancer ...

Merck and Daiichi Sankyo's HER3 antibody-drug conjugate reported a positive phase 3 result in EGFR-mutated lung cancer. Merck ...

About Ignite Proteomics Ignite Proteomics LLC, a subsidiary of IMAC Holdings, Inc., specializes in advanced RPPA technology for cancer diagnostics. As the only provider of a CLIA-accredited RPPA assay ...

(JAMA Network Open) A phase III trial of the antibody-drug conjugate patritumab deruxtecan in non-small cell lung cancer met the primary endpoint of progression-free survival, although two deaths not ...

Merck MRK announced that a phase study evaluating its Daiichi Sankyo-partnered HER3-directed DXd antibody drug conjugate (ADC ...

Daiichi Sankyo and Merck said on Tuesday that their drug, patritumab deruxtecan, met the main goal of extending the time some ...

Daiichi Sankyo and MSD (Merck & Co) have reported that the Phase III HERTHENA-Lung02 clinical trial of patritumab deruxtecan, ...

ADCs, particularly Enhertu and datopotamab deruxtecan, are showing promising results. See why I rate the stock a buy.

Researchers explored HER2 testing discordance, biomarkers of response, patient-reported outcomes, and the risk of lung-related disease.

The FDA previously rejected patritumab deruxtecan over manufacturing issues. Tuesday's study data should boost the companies' case, however.